Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: A cancer and leukemia group B study

Clinical Cancer Research

Volumn 3, Issue 11, 1997, Pages 1977-1984

  Samuels, Brian L ^a   Hollis, Donna R ^c   Rosner, Gary L ^c   Trump, Donald L ^b,d   Shapiro, Charles L ^e   Vogelzang, Nicholas J ^f   Schilsky, Richard L ^g  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c Cancer and Leukemia Group B Statistical Center   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g Cancer Leukemia Grp B Ctrl Off   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; TAMOXIFEN; VINBLASTINE;

ADULT; AGED; ARTICLE; ATAXIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; KIDNEY CARCINOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE; TAMOXIFEN; VINBLASTINE;

EID: 0030656445     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Beck, W., Cirtain, M., Danks, M., Felsted, R., Safa, A., Wolverton, J., Suttle, D., and Trent, J. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res., 47: 5455-5460, 1987.
2. Skovsgaard, T. Mechanisms of resistance to daunorubicin in ehrlich ascites tumor cells. Cancer Res., 38: 1785-1791, 1978.
3. Ferguson, P., Fisher, M., Stephenson, J., Li, D-h., Zhou, B-S., and Cheng, Y-C. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res., 48: 5956-5964, 1988.
4. Biedler, J., and Meyers, M. Multidrug resistance (Vinca alkaloids, actinomycin D, and anthracycline antibiotics). In: R. Gupta (ed.), Drug Resistance in Mammalian Cells, Vol. 2, Anticancer and Other Drugs, pp. 125-140. Boca Raton, FL: CRC Press, 1989.
5. Gerlach, J., Kartner, N., Bell, D., and Ling, V. Multidrug Resistance. Cancer Surv., 5: 25-46, 1986.
6. Juliano, R., and Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455: 152-162, 1976.
7. Scurr, R., Davey, R., Mackertich, S., Harman, D., Dowden, G., Isbister, J., and Bell, D. Detection of multidrug resistant phenotype in acute non-lymphoblastic leukemia. Lancet, 1: 135-137, 1987.
8. Marie, J., Zittoun, R., and Sikic, B. Multidrug resistance (mdr-1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood, 78: 586-592, 1991.
9. Maslak, P., Hegewisch-Becker, S., Godfrey, L., and Andreeff, M. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry, 17: 84-93, 1994.
10. Yuen, A., and Sikic, B. Multidrug resistance in lymphomas. J. Clin. Oncol., 12: 2453-2459, 1994.
11. Kang, Y., Zhan, Z., Regis, J., Alvarez, M., Robey, R., Meadows, B., Dickstein, B., Lee, J., Otsuki, T., Stetler-Stevenson, M., Jaffer, E., Solomon, D., Wilson, W., Fojo, A., and Bates, S. Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood, 86: 1515-1524, 1995.
12. Fojo, A., Ueda, K., Slamon, D., Poplack, D., Gottesman, M., and Pastan, I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA, 84: 265-269, 1987.
13. Goldstein, L., Galski, H., Fojo, A., Willingham, M., Lai, S-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G., Lieber, M., Cossman, J., Gottesman, M., and Pastan, I. Expression of a multidrug resistance gene in human tumors. J. Natl. Cancer Inst., 81: 116-124, 1989.
14. Fojo, A., Shen, D-W., Mickley, L., Pastan, I., and Gottesman, M. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug resistance gene. J. Clin. Oncol., 5: 1922-1927, 1987.
15. Yagoda, A., Petrylak, D., and Thompson, S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. North Am., 20: 303-321, 1993.
16. Yagoda, A., Abi-Rached, B., and Petrylak, D. Chemotherapy for advanced renal cell carcinoma. Semin. Oncol., 22: 42-60, 1995.
17. Swanson, D. Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma? Semin. Urol., 11: 35-40, 1993.
18. Stadler, W., Vogelzang, N., Vokes, E., Charette, J., and Whitman, G. Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a Phase II study in metastatic renal cell cancer. Cancer Chemother. Pharmacol., 31: 213-216, 1992.
19. Law, T., Ilson, D., and Motzer, R. Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest. New Drugs, 12: 143-145, 1994.
20. Law, T., Mencel, P., and Motzer, R. Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest. New Drugs, 12: 323-325, 1994.
21. Kish, J., Wolf, M., Crawford, E., Leimert, J., Bueschen, A., Neefe, J., and Flanigan, R. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma: a Southwest Oncology Group Study. Cancer (Phila.), 74: 916-919, 1994.
22. De Mulder, P., Weissbach, L., Jakse, G., Osieka, R., and Blatter, J. Gemcitabine: a Phase II study in patients with advanced renal cancer. Cancer Chemother. Pharmacol., 37: 491-495, 1996.
23. Bruntsch, U., Heinrich, B., Kaye, S., de Mulder, P., van Oosterom, A., Paridaens, R., Vermorken, J., Wanders, J., Franklin, H., Bayssas, M., et al. Docetaxel (Taxotere) in advanced renal cell cancer: a Phase II trial of the EORTC Early Clinical Trials Group. Eur. J. Cancer, 30A: 1064-1067, 1994.
24. Elson, P., Kvols, L., Vogl, S., Glover, D., Hahn, R., Trump, D., Carbone, P., Earle, J., and Davis, T. Phase II trials of 5-day vinblastine infusion, L-alanosine, acivicin, and aminothiadiazole in patients with recurrent or metastatic renal cell carcinoma. Invest. New Drugs, 6: 97-103, 1988.
25. Kuebler, J., Hogan, T., Trump, D., and Bryan, G. Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma. Cancer Treat. Rep., 68: 925-926, 1984.
26. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M., Pastan, I., and Willingham, M. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci., USA, 84: 7735-7738, 1987.
27. Hughson M., Johnson, L., Silva, F., and Kovacs, G. Nonpapillary, and papillary renal cell carcinoma: a cytogenetic and phenotypic study. Mod. Pathol., 6: 449-456, 1993.
28. Kakehi, Y., Kanamaru, H., Yoshida, O., Okhubo, H., Nakanishi, S., Gottesman, M., and Pastan, I. Measurement of multidrug-resistance messenger RNA in urogenital cancers: elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J. Urol., 139: 862-865, 1988.
29. Hart, S., Ganeshaguru, K., Hoffbrand, A., Prentice, H., and Mehta, A. Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia (Baltimore), 8: 2163-2168, 1994.
30. Chan, H. Thorner, P., Haddad, G., and Ling, V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol., 8: 689-704, 1990.
31. Chan, H., Haddad, G., Thorner, P., DeBoer, G., Lin, Y., Ondrusek, N., Yeger, H., and Ling, V. P-Glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. New Engl. J. Med., 325: 1608-1614, 1991.
32. Zamora, J., Pearce, H., and Beck, W. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol., 33: 454-462, 1988.
33. Hofsli, E., and Nissen-Meyer, J. Reversal of multidrug resistance by lipophilic drugs. Cancer Res., 50: 3997-4002, 1990.
34. Tsuruo, T., Iida, H., Tsukagoshi, S., and Sakurai, Y. Increased accumulation of vincristine and Adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res., 42: 4730-4733, 1982.
35. Ramu, A., Glaubiger, D., and Fuks, Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res., 44: 4392-4395, 1984.
36. Kirk, J., Houlbrook, S., Stuart, N., Stratford, I., Harris, A., and Carmichael, J. Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. Eur. J. Cancer, 29A: 1152-1157, 1993.
37. Foster, B., Grotzinger, K., McKoy, W., Rubinstein, L., and Hamilton, T. Modulation of induced resistance to Adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. Cancer Chemother. Pharmacol., 22: 147-152, 1988.
38. Tsurao, T., Iida, H., Kitatani, Y., Yokota, K., Tsukagoshi, S., and Sakurai, Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and Adriamycin in drug-resistant tumor cells. Cancer Res., 44: 4303-4307, 1984.
39. Dalton, W., Grogan, T., Meltzer, P., Scheper, R., Durie, B., Taylor, C., Miller, T., and Salmon, S. Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol., 7: 415-424, 1989.
40. Benson, A., Trump, D., Koeller, J., Egorin, M., Olnan, E., Witte, R., Davis, T., and Tormey, D. Phase I study of vinblastine and verapamil given by concurrent IV infusion. Cancer Treat. Rep., 69: 795-799, 1985.
41. Ozols, R., Cunnion, R., Klecker, R., Jr., Hamilton, T., Ostchega, Y., Parillo, J., and Young, R. Verapamil and Adriamycin in the treatment of drug resistant ovarian cancer patients. J. Clin. Oncol., 5: 641-647, 1987.
42. Rogan, A., Hamilton, T., Young, R., Klecker, R., and Ozols, R. Reversal of Adriamycin resistance by verapamil in human ovarian cancer. Science (Washington DC), 224: 994-996, 1984.
43. Pennock, G., Dalton, W., Roeske, W., Appleton, C., Mosley, K. Plezia, P., Miller, T., and Salmon, S. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J. Natl. Cancer Inst., 83: 105-110, 1991.
44. Kanamaru, H., Kakehi, Y., Yoshida, O., Nakanishi, S., Pastan, I., and Gottesman, M. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J. Natl. Cancer Inst., 81: 844-849, 1989.
45. Slater, L., Sweet, P., Stupecky, M., and Gupta, S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest., 77: 1405-1408, 1986.
46. Twentyman, P., Fox, N., and White, D. Cyclosporin A and its analogues as modifiers of Adriamycin and vincristine resistance in a multidrug resistant human lung cancer cell line. Br. J. Cancer. 56: 55-57, 1987.
47. Fine, R., Sachs, C., Albers, M., and Williams, A. Tamoxifen potentiates the cytotoxicity of vinblastine by increasing intracellular drug accumulation. Proc. Am. Assoc. Cancer Res., 32: 375, 1991.
48. Samuels, B., Mick, R., Vogelzang, N., Williams, S., Schilsky, R., Safa, A., O'Brien, S., and Ratain, M. Modulation of vinblastine resistance with cyclosporine: a Phase I study. Clin. Pharmacol. Ther., 54: 421-429, 1993.
49. Trump, D., Smith, D., Ellis, P., Rogers, M., Schold, S., Winer, E., Panella, T., Jordan, V., and Fine, R. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J. Natl. Cancer Inst., 84: 1811-1816, 1992.
50. Fleiss, J. L. Statistical Methods for Rates and Proportions, Ed. 2. New York: John Wiley & Sons, 1981.
51. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
52. Brookmeyer, R., and Crowley, J. A. A confidence interval for the median survival time. Biometrics, 38: 29-41, 1982.
53. Simon, R. Designs for efficient clinical trials. Oncology, 3: 43-49, 1989.
54. Yap, H-Y., Blumenschein, G., Keating, M., Hortobagyi, G., Tashima, C., and Loo, T. Vinblastine given as a continuous five-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat. Rep., 64: 279-283, 1980.
55. Rodenburg, C., Nooter, K., Herweijer, H., Seynaeve, C., Oosterom, R., Stoter, G., and Verweij, J. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell carcinoma. Ann. Oncol., 2: 305-306, 1991.
56. Poplin, E., and Baker, L. Response rates: an evolution. Cancer Chemother. Pharmacol., 34: 361-363, 1994.
57. Diehl, L., and Perry, D. A comparison of randomized concurrent control groups with matched historical control groups: are historical controls valid?, J. Clin. Oncol., 4: 1114-1120, 1986.